Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a wholly-owned pipeline of three rare disease endocrinology product candidates in clinical development.
|Recent News||More >>|
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
|Upcoming Events||More >>|
|Primary IR Contact|
|Scott T. Smith|
Chief Financial Officer
Data provided by Nasdaq. Minimum 15 minutes delayed.